Experimental CAR T-Cell therapy targets tough lymphoma
NCT ID NCT03590574
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase trial tested a new treatment called AUTO4 for people with a type of T-cell lymphoma that had come back or not responded to prior therapy. AUTO4 is a CAR T-cell therapy designed to recognize and attack cancer cells carrying a specific marker called TRBC1. The study aimed to check safety and find the right dose, but it was stopped early after enrolling only 20 participants.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
AUTO4 (a CAR T-cell therapy targeting TRBC1)
What this could lead to
If successful, this approach could offer a new treatment option for people with certain types of T-cell lymphoma that have not responded to standard therapies.
What could go wrong
This was a very early (Phase 1/2) trial with only 20 participants, and it was terminated, so results are limited. CAR T-cell therapies can cause severe side effects like cytokine release syndrome.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ANGIOIMMUNOBLASTIC T-CELL LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Freeman Hospital, The Newcastle upon Tyne Hospitals NHS Foundation Trust
Newcastle upon Tyne, United Kingdom
-
Manchester Royal Infirmary Hospital
Manchester, United Kingdom
-
Queen Elizabeth University Hospital
Glasgow, United Kingdom
-
University College London Hospitals NHS Foundation Trust
London, United Kingdom
-
Vall d'Hebron Institute of Oncology
Barcelona, Spain